Roche , managed, the loss of sales from generics for its Blockbuster more than compensate. The shareholders of an increased dividend beckons. For 2019 set by Roche further growth to the target.
in 2018, has increased Roche's sales by 7 percent to 56.8 billion Swiss francs. Thus, the group performed significantly better than the Management had made to the beginning of the year. Even disproportionately to the profit gained to pay. The operating profit increased by 14 percent to 14.8 billion, and net profit by as much as 23 percent to 10.9 billion.
The jump in earnings, Roche explains in addition to the improved operating result, particularly with the impact of US tax reform. The special items, adjusted core operating profit improved by 8 percent to 20.5 billion francs. Overall, Roche cut slightly better than the Reuters surveyed analysts had expected.
Pharma division is growing thanks to newer means of
The larger business division Pharma contributed nearly 44 billion ( 7%) to group sales. The growth was primarily driven by the newer agents such as Ocrevus for the treatment of multiple sclerosis, or cancer medicines Perjeta, Alecensa and Tecentriq.
So Ocrevus achieved an annual turnover of 2.4 billion. Thus, the drug is the most successful product launch in the history of Roche. And the demand present, also remains strong. Tecentriq approaches with sales of 772 million ( 59%) rapidly in the blockbuster status. As Blockbuster drugs are referred to with an annual turnover of over a billion.
at the same time imitation products for the older cancer have left to pay agents such as Rituxan/Mabthera or Herceptin traces in the sale - however, even less severe than feared. So sales of Rituxan/Mabthera decreased overall by 8 percent. In Europe, where Biosimilars are available, it broke the sales by 47 percent.
Biosimilars are making themselves felt
The top-selling drug Herceptin increased the total sales still slightly to nearly 7 billion. Since the mid-2018 is in Europe, launched Biosimilars conducted for this Region, but already had a sales decline of 16 percent. The pharmaceutical business generated an operating profit of 14.8 billion, the margin improved by 1.6 percentage points to 33.6 percent.
In a significant smaller area of Diagnostics, Roche generated a turnover of 12.9 billion ( 7%) an operating profit of 617 million. The margin improved by 2.6 percentage points to 4.8 percent. Roche CEO Severin Schwan showed himself satisfied with the performance: "Both divisions have achieved very good results."
increases The shareholders Roche proposes for 2018, a dividend of 8,70 Swiss francs per share, from 8.30 francs in the previous year. It would be the 32. Dividend increase in a row. Roche is also seeking to increase the payout even further in the future.
For the current year, Roche expects further growth. Specifically, the Management makes constant exchange rates sales growth in the low to mid-single-digit percent range in view. As a result, Roche is more optimistic than most analysts had expected. The Core EPS is expected to grow in step with sales growth.
A fine salary
Roche chief Swan of 2018 earned a little more than the year before. In total, he received 11.8 million CHF to 11.7 million in 2017. For comparison: since February President of the Novartis-CEO, Vas Narasimhan was compensated in his first year in office, with just under 6.7 million Swiss francs.
The basic content of Swan's fraud, as in the previous year: 4 million francs. Slightly higher payments by the employer for pension and insurance companies, as well as the other payments.
All members of the Roche Executive Committee, together received in the reporting year, 39.3 million francs, to 40.2 million in 2017, as the on Thursday published the annual report of Roche.
Chairman of the Board Christoph Franz earned 5.7 million Swiss francs, the same as in the previous year. Novartis-President Jörg Reinhard was compensated with 3.8 million Swiss francs.
Created: 31.01.2019, 10:05 p.m.